ARA-290

Plain-English version: ARA-290 is a lab-made peptide that borrows one useful trick from erythropoietin (EPO) while leaving the risky part behind. EPO is famous for boosting red blood cells — which is why it is abused in endurance sports and why the real hormone can thicken blood and raise clot risk. But EPO quietly does something else too: it protects stressed tissue, calms inflammation, and helps injured nerves recover. ARA-290 was engineered to deliver only that second job.

The peptide corresponds to a specific stretch on the surface of EPO's "helix B" — a region that touches a different receptor than the one responsible for making red blood cells. That difference is the entire point of the molecule.^[4]

The two-receptor story

Native erythropoietin can signal through two different receptor setups:

• The classical EPO receptor (a homodimer) — this is the one that drives red blood cell production, and also the one linked to EPO's dangerous effects like raised hematocrit and thrombosis.
• The innate repair receptor, or IRR — a heterodimer built from the EPO receptor plus the beta-common receptor. This one mediates EPO's anti-inflammatory, anti-cell-death, tissue-protective effects, and it appears mainly on cells that are injured or under stress.^[4]

ARA-290 was designed to bind and activate the innate repair receptor without activating the classical EPO receptor. In practice, human trials confirmed the design goal: participants did not show the red-blood-cell changes you would expect from EPO.

Where it came from and where it stands

ARA-290 (development name cibinetide) came out of erythropoietin research pioneered by Anthony Cerami and Michael Brines, and was developed by Araim Pharmaceuticals. It progressed through Phase 1 and Phase 2 human trials in the early-to-mid 2010s and then development stalled — there is no completed Phase 3 trial and no marketing approval anywhere in the world.

Per secondary and regulatory reporting, the FDA granted ARA-290 Orphan Drug and Fast Track designation for neuropathic pain in sarcoidosis, plus a separate Orphan Drug designation aimed at preventing graft loss in pancreatic islet transplantation. It is important to be precise here: those are development incentives, not approvals, and we were not able to confirm them against a primary FDA database in this review — treat them as reported rather than verified. Bottom line: ARA-290 is an investigational compound sold only as a "not for human use" research peptide.

The takeaway: ARA-290 flips on a tissue-repair "receptor switch" (the innate repair receptor) that is mostly present on damaged or inflamed cells. Turning it on tells those cells to stop self-destructing, dials down inflammation, and supports nerve repair — all without touching the machinery that makes red blood cells.

1. Selective activation of the innate repair receptor (IRR)

This is the core mechanism and the reason ARA-290 exists. The IRR is a heterodimer of the EPO receptor and the beta-common receptor, and it is upregulated specifically in tissues that are injured, ischemic, or inflamed. Because ARA-290 targets this receptor rather than the classical erythropoietic one, its effects are concentrated where tissue is already in trouble rather than acting broadly on the bloodstream.^[4]

2. Anti-inflammatory signaling

Activating the innate repair receptor helps rebalance the local immune response — shifting cells away from a sustained pro-inflammatory state toward resolution and repair. In the EPO/IRR literature this pathway is described as taming an overactive innate immune response, which is a plausible route to the symptom improvements seen in inflammatory conditions like sarcoidosis.^[4]

3. Anti-apoptotic (anti-cell-death) protection

A central feature of EPO's tissue-protective arm is keeping stressed cells alive long enough to recover instead of dying off. ARA-290 is intended to reproduce this protective signaling in injured tissue without the erythropoietic effect.

4. Nerve repair — with objective evidence

The most striking mechanistic support in humans is structural, not just symptomatic. In a sarcoidosis trial, daily ARA-290 not only improved neuropathic symptoms but also increased corneal small nerve fiber density measured by corneal confocal microscopy — an objective, imaging-based sign that tiny nerves were regenerating, not just that patients felt better.^[2]

5. A pain-channel mechanism — animal evidence only

One preclinical study in mice and cultured cells reported that ARA-290 relieves pain in part by acting on the TRPV1 channel, a key sensor involved in pain and inflammation — framed as a bridge between the immune system and pain signaling. This is a promising idea, but it is animal and cell-culture data only and has not been demonstrated in humans, so it should be read as a hypothesis rather than an established human mechanism.^[5]

Pharmacokinetics note

ARA-290 has a very short plasma half-life (on the order of minutes). This is common for peptides that act as a trigger: the molecule doesn't need to linger in the blood because it sets off longer-lasting downstream signaling inside cells. It also helps explain why intermittent dosing (for example, three times weekly) was studied rather than continuous exposure.

Read this first: Unlike most research peptides, ARA-290 actually has human trial data — which is a genuine credibility point. But those trials are small (dozens of patients each), early-phase, and were never followed by a large confirmatory study. Below, each claim is paired with what was studied, how big the effect was, and where the evidence stops. Nothing here is an approved treatment.

Small fiber neuropathy in sarcoidosis (the strongest human signal)

Plain-English claim: In people whose sarcoidosis had damaged the tiny nerves that carry pain and temperature sensation, ARA-290 reduced neuropathic symptoms.

What was studied: A randomized, double-blind, placebo-controlled pilot enrolled 22 sarcoidosis patients with small fiber neuropathy symptoms (12 on ARA-290, 10 on placebo), dosing 2 mg intravenously three times weekly for 4 weeks.^[1]

Effect size: On the Small Fiber Neuropathy Screening List (SFNSL) symptom score, the ARA-290 group improved by roughly -11.5 points versus -2.9 for placebo (p<0.05), with additional gains in pain and physical-functioning quality-of-life measures.^[1]

Limitation: Only 22 patients, only 4 weeks, single center. A positive pilot is a reason to run a larger trial, not proof of a treatment effect.

Structural nerve regeneration (an objective endpoint, not just a questionnaire)

Plain-English claim: ARA-290 didn't just make people report feeling better — imaging showed their small nerves actually grew back.

What was studied: A separate sarcoidosis-associated small fiber neuropathy study used 28 days of daily subcutaneous ARA-290 and added corneal confocal microscopy, an imaging technique that counts tiny nerve fibers in the eye's cornea as a window on small-fiber health.^[2]

Effect size: ARA-290 significantly improved neuropathic symptoms and increased corneal nerve fiber density. Cutaneous pain thresholds also improved (cold pain threshold p=0.027; hot pain threshold p=0.032), and the benefit was reported as sustained through 16 weeks of follow-up.^[2]

Limitation: Still small and early-phase. The objective endpoint strengthens the case, but this remains hypothesis-generating, not a demonstrated cure for neuropathy.

Type 2 diabetes: metabolic and neuropathic symptoms

Plain-English claim: In people with type 2 diabetes, a month of ARA-290 was associated with better blood-sugar and cholesterol markers plus fewer neuropathy symptoms.

What was studied: Patients with type 2 diabetes self-administered 4 mg of subcutaneous ARA-290 daily for 28 days, followed by a further month of observation (56 days total).^[3]

Effect size: The ARA-290 group showed improvement in HbA1c (a 3-month average blood-sugar marker) and in lipid (cholesterol) profiles across the observation window, alongside neuropathic symptom improvement, with no safety issues identified.^[3]

Limitation: Small, short, early-phase, and never confirmed in a larger trial. Metabolic markers moving over 56 days is encouraging but not the same as demonstrating durable diabetes benefit.

Pain relief via TRPV1 — animal evidence

Plain-English claim: Part of ARA-290's pain relief may come from acting directly on a pain-sensing channel.

What was studied: A mouse and HEK293 cell study reported ARA-290 relieves pathophysiological pain by targeting the TRPV1 channel.^[5]

Limitation: This is animal and cell-culture data. It has not been shown in humans and should not be presented as a proven human benefit.

What is NOT established

• No Phase 3 trial exists. Everything above is Phase 1/2-scale. The compound has not cleared the bar that regulators require for approval.
• No approved indication. None of these uses is FDA-approved.
• Broad "healing," anti-aging, or performance claims are unsupported. The human data is confined to sarcoidosis neuropathy and type 2 diabetes; anything beyond that is extrapolation.

Important framing: The doses below are the ones used in published human research studies. They are reported here to accurately describe the science — not as a protocol to follow. ARA-290 is not an approved medicine, and there is no established, validated dosing for any use outside those trials.

Doses used in published trials

Study population	Dose	Route	Frequency	Duration
Sarcoidosis small fiber neuropathy (pilot RCT)	2 mg	Intravenous (IV)	3× weekly	4 weeks[1]
Sarcoidosis (corneal nerve study)	Daily dosing	Subcutaneous (SC)	Once daily	28 days[2]
Type 2 diabetes	4 mg	Subcutaneous (SC)	Once daily	28 days + 28-day follow-up[3]

A correction worth flagging: Some ARA-290 write-ups (including an earlier version of this page) describe the sarcoidosis pilot as "2 mg subcutaneous three times weekly." That is wrong on the route — the pilot's 2 mg three-times-weekly regimen was given intravenously, not subcutaneously.^[1] Later sarcoidosis and diabetes studies used subcutaneous daily dosing.^[2][3] Getting the route right matters: IV and SC are not interchangeable.

Why intermittent dosing worked despite a short half-life

ARA-290 clears from plasma within minutes, yet trials still saw effects with intermittent dosing. This fits the mechanism: the peptide acts as a trigger for longer-lasting downstream signaling through the innate repair receptor, so it doesn't need to remain in the blood to keep working. That is why a three-times-weekly schedule (in the pilot) or once-daily dosing (in later studies) was sufficient rather than requiring a continuous infusion.

Reconstitution math (worked example)

Research-grade ARA-290 ships as a lyophilized (freeze-dried) powder and must be reconstituted with bacteriostatic water before it can be measured into a syringe. The arithmetic is the same as for any peptide:

• Concentration = total peptide ÷ water added. Example: a 4 mg vial reconstituted with 2 mL of bacteriostatic water gives 4 mg ÷ 2 mL = 2 mg/mL (equivalently, 2000 mcg/mL).
• Volume for a given dose = dose ÷ concentration. To draw a 2 mg dose at 2 mg/mL: 2 mg ÷ 2 mg/mL = 1.0 mL. On a standard U-100 insulin syringe, 1.0 mL = 100 units.
• If you instead reconstitute the same 4 mg vial with 1 mL of water, the concentration doubles to 4 mg/mL, and a 2 mg dose becomes 0.5 mL (50 units).

Use the peptide calculator to check these volumes, and the reconstitution guide for step-by-step technique. Reconstitute gently — add water down the vial wall, swirl rather than shake.

Cycle length and timing

Published trials ran short courses of about 28 days (four weeks). ARA-290 was administered without strict meal or time-of-day requirements in these studies. There is no validated concept of "cycling" ARA-290 outside a trial context because it has never been studied long-term or in a general population.

Storage

• Lyophilized powder: -20°C for long-term storage; 2–8°C for shorter periods.
• Reconstituted solution: refrigerate at 2–8°C and use within the window your supplier specifies. Do not freeze reconstituted peptide, and discard if the solution becomes cloudy or discolored.

The headline: In the small human trials published so far, ARA-290 was well tolerated, with no serious drug-related adverse events and — by design — no rise in red blood cells. The catch is sample size: these trials enrolled only dozens of people over a few weeks, so a clean safety record here does not prove long-term or large-population safety.

The defining safety feature: no erythropoietic effect

ARA-290's whole reason for existing is to separate EPO's tissue protection from its blood-thickening. Across the verified trials, that separation held up: no meaningful changes in hematocrit or hemoglobin were reported, consistent with a molecule engineered to skip the classical EPO receptor.^[1][4] This is the key contrast with erythropoietin itself, which carries well-known risks of erythrocytosis, hypertension, and thrombosis.

Reported and plausible side effects

Effect	What the evidence says	Notes
Serious drug-related adverse events	None reported	Across the published Phase 1/2 trials[1][3]
Raised red blood cells / hematocrit	Not observed	Confirms the EPO-receptor-independent design[1]
Injection-site reactions	Plausible but not quantified	Common with any injected peptide; frequency not detailed in the abstracts reviewed — low certainty
Headache	Plausible but not quantified	Reported anecdotally; not a firm trial-derived frequency — low certainty

Honesty note on frequencies: Injection-site reactions and headache are commonly listed for ARA-290, but the trial abstracts we verified did not quantify them. Treat any specific frequency claim ("common," "occasional") as low-certainty rather than established.

Who should be cautious or avoid it

• Pregnancy and breastfeeding: no controlled data — avoid.
• Known hypersensitivity to ARA-290 or EPO-derived peptides.
• Active malignancy: EPO itself carries oncology concerns because some tumors express EPO receptors. ARA-290 is designed to avoid the classical EPO receptor, which theoretically mitigates this — but there is no controlled data in cancer patients, so this is unproven. Anyone with active cancer should not treat "theoretically safer" as "safe."
• Severe kidney or liver impairment, and children: not studied; pharmacokinetics in these groups are uncharacterized.

Drug interactions

• Erythropoiesis-stimulating agents (EPO, darbepoetin): the mechanisms are receptor-distinct, but combined use has not been studied.
• Immunosuppressants: ARA-290 acts on innate-immune/anti-inflammatory pathways; whether it opposes or adds to specific immunosuppressants is not characterized.
• Diabetes medications: given the metabolic signals seen in the diabetes trial, anyone combining it with glucose-lowering drugs would need to watch blood sugar — though again, this is not a studied combination.

What to do if you experience side effects

• Injection-site reactions: rotate sites and review technique; these are typically mild and self-limiting.
• Persistent headache or flu-like symptoms: reduce frequency; if symptoms persist beyond a week, stop and evaluate other causes.
• Any allergic reaction (rash, hives, trouble breathing): discontinue immediately and seek emergency care.

For broader context on peptide safety, see Are Peptides Safe?

Bottom line: ARA-290 is not an approved drug and is sold only as a research chemical, which means product quality is entirely on the buyer to verify. With an unregulated peptide, contamination or mislabeling can be a bigger practical risk than the molecule itself.

Legal and regulatory status

• Not FDA-approved for any indication. Development stalled after Phase 2, with no Phase 3 trial and no marketing approval anywhere.
• Reported designations: secondary sources describe FDA Orphan Drug and Fast Track designation for sarcoidosis neuropathic pain, plus Orphan Drug designation for islet-transplant graft loss. These are development incentives, not approvals, and we did not confirm them against a primary FDA database in this review.
• Sold "not for human use": research-grade ARA-290 is labeled for laboratory research only.

For the full picture on peptide legality, see Are Peptides Legal?

Quality indicators to demand

• Batch-specific third-party Certificate of Analysis (COA): it should reference your exact lot number, not a generic sample.
• HPLC purity testing (look for high purity, e.g. ≥98%) and mass spectrometry identity confirming the correct peptide.
• Endotoxin (LAL) testing for anything intended for injection.
• Proper packaging: lyophilized powder in a sealed, light-protected vial.

Red flags

• No COA, or a COA from the seller rather than an independent lab.
• Pre-mixed liquid "ready to use" product (shorter shelf life, higher contamination risk).
• Prices far below the market average.
• Any "for human use," dosing, or health-benefit claims on the label — a sign the vendor is ignoring the regulations that govern research chemicals.

See the peptide storage guide for handling once a vial arrives.